NCT03242668

Brief Summary

To access the analgesic efficacy of patient controlled thoracic paravertebral analgesia.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jun 2016

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2016

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2017

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2017

Completed
24 days until next milestone

First Submitted

Initial submission to the registry

July 25, 2017

Completed
14 days until next milestone

First Posted

Study publicly available on registry

August 8, 2017

Completed
Last Updated

August 8, 2017

Status Verified

August 1, 2017

Enrollment Period

1 year

First QC Date

July 25, 2017

Last Update Submit

August 3, 2017

Conditions

Keywords

paravertebral block,PVC,PCA

Outcome Measures

Primary Outcomes (1)

  • VAS score at rest and on coughing

    Using VAS scale (Atrazennica)

    72 hours

Secondary Outcomes (5)

  • Analgesia effects on respiratory function

    three postoperative consecutive days

  • Arterial blood gas values

    three postoperative consecutive days

  • The number dermatome inhibition

    three postoperative consecutive days

  • Rescue analgesia

    three postoperative consecutive days

  • Patient's satisfaction

    three postoperative consecutive days

Other Outcomes (3)

  • Side effects and complications

    three postoperative consecutive days

  • Heart rate

    three postoperative consecutive days

  • Blood pressure

    three postoperative consecutive days

Study Arms (1)

PVB using PVC for PCA in VATS

EXPERIMENTAL

The VATS was performed.Paravertebral space was identified by loss of resistance technique combined with video-assisted inside thoracic space before chest close.PVC was inserted.Initiated dose of 0.3ml/kg of Bupivacaine Hydrochloride 1.25mg/ml and Fentanyl Citrate 2 micrograms/ml was administered then continued PCA with background rate 3ml/h, bolus dose 2ml was infused through PVC.

Procedure: VATSProcedure: PVB using PVCDrug: PCA

Interventions

VATSPROCEDURE

General anesthesia was induced with 2.0 mg/kg of propofol, 2.0 mg/kg of fentanyl, and 1.0 mg kg/1 of rocuronium and maintained with continuous infusion 6-12mg/kg/h of propofol,injected 2.0 mg/kg of fentanyl and 0.15 mg/ kg of rocuronium every 30 minutes . All patients were intubated with a double-lumen endobronchial tube for one-lung ventilation.The VATS (Video-Assisted Thoracic Surgery) was performed.

Also known as: Video-Assisted Thoracic Surgery
PVB using PVC for PCA in VATS
PVB using PVCPROCEDURE

At the end of the surgery, the upper edge of the spinous process of the thoracic vertebral body was recognized. With an epidural needle (Tuohy 22 G; Braun, Melsungen, Germany), the injection point was punctured 2 cm lateral to the midline. The paravertebral space was entered by advancing the Tuohy needle over the superior border of the transverse process. Once in the right place, the PVC was placed through the needle, checking the tip remained placed when removing the needle. The advance of the needle and the entering of the catheter into the paravertebral space were verified all the time by the surgeon using the camera. The PVC (Paravertebral Catheter ) was inserted at this point preversed at this area.

Also known as: Paravertebral block using paravertebral catheter
PVB using PVC for PCA in VATS
PCADRUG

PVC was inserted.Initiated dose of 0.3ml/kg of Bupivacaine Hydrochloride 1.25mg/ml and Fentanyl Citrate 2 micrograms/ml was administered then continued PCA (Perfusor space pump,Germany)with background rate 3ml/h, bolus dose 2ml was infused through PVC.

Also known as: Patient controlled analgesia
PVB using PVC for PCA in VATS

Eligibility Criteria

Age20 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • American Society of Anesthesiologists class I to III risk undergoing elective VATS, aged 32-72 years, scheduled for lung resection surgery.

You may not qualify if:

  • Patients who refused to participate, less than 18 years of age, ASA physical status 3 or more,, allergy to any of the study drugs, patients having any contraindication to placement of PVB, kyphoscoliosis, presence of acute herpes zoster, chronic pain syndrome, chronic analgesic use and psychiatric disease.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Vietnam Military Medical University

Hanoi, Vietnam

Location

MeSH Terms

Conditions

Pain, Postoperative

Interventions

Thoracic Surgery, Video-AssistedPassive Cutaneous AnaphylaxisAnalgesia, Patient-Controlled

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Intervention Hierarchy (Ancestors)

ThoracoscopyEndoscopyDiagnostic Techniques, SurgicalDiagnostic Techniques and ProceduresDiagnosisVideo-Assisted SurgeryMinimally Invasive Surgical ProceduresSurgical Procedures, OperativeThoracic Surgical ProceduresSkin TestsImmunologic TestsClinical Laboratory TechniquesInvestigative TechniquesImmunologic TechniquesAntigen-Antibody ReactionsImmune System PhenomenaAnalgesiaAnesthesia and Analgesia

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Model Details: 30 patients, with American Society of Anesthesiologists class I to III risk undergoing elective VATS, aged 32-72 years, scheduled for lung resection surgery , were enrolled in this randomised observer blinded prospective clinical study. Patients who refused to participate, less than 18 years of age, ASA physical status 3 or more, allergy to any of the study drugs, patients having any contraindication for paravertebral block, kyphoscoliosis, presence of acute herpes zoster, chronic pain syndrome, chronic analgesic use and psychiatric disease were excluded from this study.
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Corresponding author,Clinical Research

Study Record Dates

First Submitted

July 25, 2017

First Posted

August 8, 2017

Study Start

June 1, 2016

Primary Completion

June 1, 2017

Study Completion

July 1, 2017

Last Updated

August 8, 2017

Record last verified: 2017-08

Locations